Aclaris Therapeutics (ACRS) Current Deferred Revenue (2024 - 2026)

Aclaris Therapeutics' Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $4.0 million for Q1 2026.

• On a quarterly basis, Current Deferred Revenue rose 2.16% year-over-year to $4.0 million in Q1 2026; TTM through Mar 2026 was $4.0 million, a 2.16% increase from a year earlier, with the FY2025 full-year figure at $3.9 million, up 1.36% from the prior year.
• Current Deferred Revenue advanced to $4.0 million in Q1 2026 per ACRS's latest filing, from $3.9 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $25.8 million in Q2 2024 and bottomed at $3.8 million in Q3 2024.
• The 3-year median for Current Deferred Revenue is $3.9 million (2025), against an average of $6.6 million.
• Biggest YoY gain for Current Deferred Revenue was 4.25% in 2025; the steepest drop was 84.83% in 2025.
• Year by year, Current Deferred Revenue stood at $3.9 million in 2024, then advanced by 1.36% to $3.9 million in 2025, then gained by 0.74% to $4.0 million in 2026.
• Per Business Quant, the three latest ACRS Current Deferred Revenue figures stand at $4.0 million (Q1 2026), $3.9 million (Q4 2025), and $3.9 million (Q3 2025).